English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  52881759    在线人数 :  665
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"yau t"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 1-25 / 43 (共2页)
1 2 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
國立成功大學 2023 Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial Tempero, M.A.;Pelzer, U.;O'Reilly, E.M.;Winter, J.;Oh, D.-Y.;Li, C.-P.;Tortora, G.;Chang, H.-M.;Lopez, C.D.;Bekaii-Saab, T.;Ko, A.H.;Santoro, A.;Park, J.O.;Noel, M.S.;Frassineti, G.L.;Shan, Y.-S.;Dean, A.;Riess, H.;Van, Cutsem E.;Berlin, J.;Philip, Philip P.;Moore, Moore M.;Goldstein, D.;Tabernero, J.;Li, M.;Ferrara, S.;Le, Bruchec Y.;Zhang, G.;Lu, B.;Biankin, A.V.;Reni, M.;Epstein, R.;Vasey, P.;Shapiro, J.;Burge, M.;Chua, Y.J.;Harris, M.;Pavlakis, N.;Tebbutt, N.;Prager, G.;Dittrich, C.;L�ngle, F.;Philipp-Abbrederis, K.;Greil, R.;St�ger, H.;Girschikofsky, M.;Kuehr, T.;Van, Laethem J.-L.;Laurent, S.;Dhani, N.;Ko, Y.J.;Dowden, S.;Kavan, P.;Tehfe, M.�.;Kubala, E.;Kohoutek, M.;Pfeiffer, Pfeiffer P.;Yilmaz, M.;Parner, V.;Salminen, T.;Soveri, L.-M.;Korkeila, E.;Osterlund, P.;Taieb, J.;Tougeron, D.;Artru, P.;Caroli-Bosc, F.X.;Guimbaud, R.;Turpin, A.;Walter, T.;Bachet, J.B.;Kunzmann, V.;Kreth, F.;Block, A.;Venerito, M.;Oettle, H.;Karthaus, M.;Trojan, J.;Folprecht, G.;Lerch, M.;Kullmann, F.;Reiser, M.;Heinemann, V.;W�rns, M.-A.;Schulz, H.;Garlipp, B.;Yau, T.;Chan, L.S.;Juhasz, B.;Landherr, Landherr L.;Pinter, T.;Bodoky, G.;Kah�n, Z.;McDermott, R.;Power, D.;Gianni, L.;Siena, Siena S.;Milella, Milella M.;Falcone, A.;Berardi, R.;Bagal�, C.;Di, Costanzo F.;Roila, F.;Ardizzoni, Ardizzoni A.;Maiello, E.;Fanello, S.;Wilmink, J.;Willem, De Groot J.;Creemers, G.;Barroso, E.;Rodrigues, T.;Sarmento, C.;Chee, Chee C.E.;Tai, D.;Mercade, T.M.;Medina, Medina M.H.;Mena, A.C.;Santasusana, J.M.;Flor, Oncala M.J.;Martin, C.G.;Lopez, R.;Mu�oz, A.;Garcia, R.V.;Ales, I.;S�ez, B.L.;Rivera, F.;Sastre, J.;Wu, C.-C.;Tien, Y.-W.;Chan, D.-C.;Hwang, T.-L.;Evans, J.;Wadsley, J.;Corrie, P.;Biankin, A.;Ko, A.;Cardin, D.;Chiorean, E.;Bendell, J.;Noonan, A.;Kindler, H.;Fernando, N.;Beg, M.;George, T.;Noel, M.;Loconte, N.;Arena, F.;Posey, J.;Malhotra, R.;Lopez, C.;Sohal, D.;McWilliams, R.;Brenner, W.;Womack, M.;Seth, R.;Lyer, R.;Bahary, N.;Marsh, R.;Ramirez, Ramirez R.;Chua, Chua C.;Reeves, J.;Manji, G.;El-Khoueiry, A.;Weaver, R.;Sahai, V.;Messersmith, W.;Dreicer, R.;Zakari, A.;Bullock, A.;Musher, B.;Borad, M.;Kim, E.;Bajor, D.;Huyck, T.;Hatoum, Hatoum H.;Xiong, H.;Pasche, B.;Lacy, J.;Olowokure, Olowokure O.;Cohn, A.;Richards, D.;Martin, R.;Paulson, A.;Fanta, P.;Krishnamurthi, S.;Oberstein, P.;Fuloria, J.
國家衛生研究院 2022-09 Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan Yau, T;Tai, D;Chan, SL;Huang, YH;Choo, SP;Hsu, C;Cheung, TT;Lin, SM;Yong, WP;Lee, J;Leung, T;Shum, T;Yeung, CSY;Tai, AY;Law, ALY;Cheng, AL;Chen, LT
臺大學術典藏 2022-08-19T06:48:43Z Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Wang Y.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Yau T.; Kaseb A.O.; Ryoo B.-Y.; He A.R.; CHIH-HUNG HSU; Zhang W.; Koeppen H.; Lu S.; Guan Y.; de Galarreta M.R.; Abbas A.R.; Zhu A.X.
臺大學術典藏 2022-08-19T00:20:37Z Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T.
臺大學術典藏 2022-08-19T00:20:36Z Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014) Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.
臺大學術典藏 2022-08-19T00:20:32Z Novel systemic therapy for hepatocellular carcinoma Dong Y.; Liu T.-H.; Yau T.; CHIUN HSU
臺大學術典藏 2022-06-10T06:10:59Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏 2022-06-10T06:10:56Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏 2022-03-10T06:14:59Z Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F.
臺大學術典藏 2022-02-21T02:04:35Z Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG
臺大學術典藏 2022-02-21T02:04:35Z Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y.
臺大學術典藏 2022-02-21T02:04:32Z Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I.
國立成功大學 2022 A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P.
臺大學術典藏 2021-09-01T01:53:56Z Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012 Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG; Kang Y.-K.; de Lima Lopes G.
臺大學術典藏 2021-08-31T06:29:37Z Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R.
臺大學術典藏 2021-08-31T06:29:19Z Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators
臺大學術典藏 2021-08-31T06:29:17Z Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:16Z Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:16Z Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L.
臺大學術典藏 2021-08-31T06:29:14Z Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A.
臺大學術典藏 2021-08-31T06:29:14Z Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:13Z Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M.
臺大學術典藏 2021-08-11T03:46:38Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏 2021-08-11T03:46:35Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏 2021-07-03T03:34:34Z Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics Yau T.; PEI-JER CHEN; Chan P.; Curtis C.M.; Murphy P.S.; Suttle A.B.; Gauvin J.; Hodge J.P.; Dar M.M.; Poon R.T.

显示项目 1-25 / 43 (共2页)
1 2 > >>
每页显示[10|25|50]项目